Journal article
Cordyceps inhibits ceramide biosynthesis and improves insulin resistance and hepatic steatosis
Scientific reports, Vol.12(1), pp.7273-7273
05/04/2022
DOI: 10.1038/s41598-022-11219-3
PMCID: PMC9068713
PMID: 35508667
Abstract
Ectopic ceramide accumulation in insulin-responsive tissues contributes to the development of obesity and impairs insulin sensitivity. Moreover, pharmacological inhibition of serine palmitoyl transferase (SPT), the first enzyme essential for ceramide biosynthesis using myriocin in rodents reduces body weight and improves insulin sensitivity and associated metabolic indices. Myriocin was originally extracted from fruiting bodies of the fungus Isaria sinclairii and has been found abundant in a number of closely related fungal species such as the Cordyceps. Myriocin is not approved for human use but extracts from Cordyceps are routinely consumed as part of traditional Chinese medication for the treatment of numerous diseases including diabetes. Herein, we screened commercially available extracts of Cordyceps currently being consumed by humans, to identify Cordyceps containing myriocin and test the efficacy of Cordyceps extract containing myriocin in obese mice to improve energy and glucose homeostasis. We demonstrate that commercially available Cordyceps contain variable amounts of myriocin and treatment of mice with a human equivalent dose of Cordyceps extract containing myriocin, reduces ceramide accrual, increases energy expenditure, prevents diet-induced obesity, improves glucose homeostasis and resolves hepatic steatosis. Mechanistically, these beneficial effects were due to increased adipose tissue browning/beiging, improved brown adipose tissue function and hepatic insulin sensitivity as well as alterations in the abundance of gut microbes such as Clostridium and Bilophila. Collectively, our data provide proof-of-principle that myriocin containing Cordyceps extract inhibit ceramide biosynthesis and attenuate metabolic impairments associated with obesity. Moreover, these studies identify commercially available Cordyceps as a readily available supplement to treat obesity and associated metabolic diseases.
Details
- Title: Subtitle
- Cordyceps inhibits ceramide biosynthesis and improves insulin resistance and hepatic steatosis
- Creators
- Ying Li - University of UtahChad Lamar Talbot - University of UtahBhawna Chandravanshi - University of IowaAlec Ksiazek - University of IowaAyushi Sood - University of IowaKamrul Hasan Chowdhury - University of UtahJ Alan Maschek - University of UtahJames Cox - University of UtahAdhini Kuppuswamy Satheesh Babu - University of UtahHenry A Paz - University of Arkansas at FayettevillePon Velayutham Anandh Babu - University of UtahDavid K Meyerholz - University of IowaUmesh D Wankhade - University of Arkansas at FayettevilleWilliam Holland - University of UtahE Shyong Tai - National University of SingaporeScott A Summers - University of UtahBhagirath Chaurasia - Carver College of Medicine, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City
- Resource Type
- Journal article
- Publication Details
- Scientific reports, Vol.12(1), pp.7273-7273
- DOI
- 10.1038/s41598-022-11219-3
- PMID
- 35508667
- PMCID
- PMC9068713
- NLM abbreviation
- Sci Rep
- eISSN
- 2045-2322
- Grant note
- 7-21-JDF-033 / ADA Foundation 2019-67018-29250 / U.S. Department of Agriculture DK124326 / NIDDK NIH HHS DK115824 / NIDDK NIH HHS DK108833 / NIDDK NIH HHS JDRF 3-SRA- 581 2019-768-A-B / Juvenile Diabetes Research Foundation United States of America
- Language
- English
- Date published
- 05/04/2022
- Academic Unit
- Pathology; Fraternal Order of Eagles Diabetes Research Center; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984256160202771
Metrics
16 Record Views